Colon cancer is one of the carcinomas that is resistant to a variety of therapies. To develop a new therapy by regulating the activated K-ras gene in colon cancers, we prepared synthetic DNA encoding the ribozyme (catalytic RNA), and inserted it into an expression vector (LNCX) originated from a retrovirus. Transfection of the vector into SW620 human colon cancer cells brought about significant suppression of K-ras mRNA synthesis and inhibition of the cell growth. Studies in athymic mice, in which K-ras ribozyme-introduced SW620 cells were transplanted, also revealed a marked reduction of tumor growth in vivo. Furthermore, the ribozyme-introduced tumors became more sensitive to treatment with anti-cancer drugs such as cisplatin, adriamycin, 5-fluorouracil, vincristine, and etoposide. These data suggest that the possible efficacy of anti-K-ras ribozyme increases the chemosensitivity of human colon cancers as well as the inhibitory effect on the growth of human colon cancers. Cancer Gene Therapy (2000) 7, 495-500
C olon cancer is one of the incurable carcinomas in humans because of its poor sensitivity to chemotherapy and/or radiotherapy, despite the great efforts made to develop an effective therapy. Antisense therapeutics, which exploit the high degree of specificity offered by the base pair recognition of genetic information 1 may have promising therapeutic value in cancers, including colon cancers, because of their specificity in targeting gene products with minimal side effects. This therapy has the ability to suppress neoplastic phenotypes in cancer cells [2] [3] [4] and bring about an inhibition of chimeric bcr-abl gene expression in Philadelphia chromosome-positive cells in chronic myeloid leukemia, such as a reduction in bcr-abl mRNA at p210bcr-abl levels. 5, 6 Successful results in antisense technology, however, have been demonstrated only in in vitro or culture systems. Further, the efficacy is rather transient for the reversion of tumorigenicity, indicating the need to develop more effective methods.
Given the previous success of ribozyme-mediated inhibition of gene expression, 5 we constructed a naked plasmid DNA vector into which a hammerhead ribozyme was inserted. We have explored the potential of using this ribozyme as a therapeutic modulator. Here, we show that electroporation-mediated transfer of the ribozyme, which was constructed to target K-ras mRNA, may be a useful therapeutic strategy for colon cancer in vivo as well as in vitro.
MATERIALS AND METHODS

Reagents
5-fluorouracil (5-FU) and adriamycin (ADR) (Kyowa Hakko
Kyogyo, Tokyo, Japan), vincristine (VCR) (Shionogi Seiyaku, Osaka, Japan), cisplatin (CDDP), and etoposide (VP16) (Bristol Myers Squibb, Tokyo, Japan) were dissolved to various concentrations with distilled water. [ 3 H]thymidine (dThd) was obtained from New England Nuclear (Boston, Mass).
Cells
Human colon carcinoma SW620 cells were obtained from the American Type Culture Collection (ATCC) (Manassas, Va) and maintained in Dulbecco's modified Eagle's minimum essential medium with 10% fetal bovine sera (Life Technologies, Grand Island, NY), penicillin (500 g/mL), and streptomycin (5000 g/mL) at 5% CO 2 . The mutation in codon 12 of the K-ras gene in SW620 cells converted homologous GGC (gly) to GUC (val), as confirmed by sequence analysis. Thymidine uptake for DNA synthesis was determined by the measurement of the rate of [ 3 H]dThd incorporation into trichloroacetic acid-precipitable material. 4 Colony formation in soft agar was performed as described previously. 4 For cytotoxicity, a 50% inhibition of cell growth (IC 50 ) of these cells for the drugs was determined by a dye reduction assay using 3-(4,5-dimethythiazol-2-yl)-2,5-diphenyl-tetrazolium bromide (MTT) (Sigma, St. Louis, Mo). A total of 3000 cells in each group were incubated in a 35-mm dish for 24 hours and treated with 7 different concentrations of each drug for the indicated number of hours. After being washed once with phosphate-buffered saline (PBS), cells were incubated for 5 days and harvested with treatment of trypsin for MTT assay.
Genes
Human K-ras cDNA (no. 41026) and human H-ras cDNA (pT24-C3, no.41000) were obtained from ATCC. The sequence of the RNA transcript of the activated K-ras targeted by the ribozyme is encoded by the following nucleotides: Target-activated K-ras mRNA (exon 1, 1697-1712 nucleotides), 5Ј-AGUUGGAGCUGUUGGCGUAGGCA-3Ј; K-ras ribozyme, 5Ј-UGCCUACGCCCUGAUGAGUCCGUGAG-GACGAA-ACAGCUCCAACU-3Ј. This hammerhead ribozyme was constructed with the same stem loop region and distinct flanking sequences complementary to the substrate RNA, essentially as described by Haseloff and Gerlach (Fig  1) . 7 The procedure of polymerase chain reaction (PCR) and reverse transcriptase (RT)-PCR was performed according to a commercially available protocol (GeneAmp, Perkin-ElmerCetus, Foster City, Calif). The preparations of total RNA, electrophoresis on horizontal agarose gels, hybridization, and radioactive densitometric analysis were performed as described previously. 8 
Plasmid construction
Anti-K-ras ribozyme as the cDNA was cloned into the HindIII sites of the plasmid pLNCX with a 6.6-kb size (Fig 1) 
Transfection studies
The subconfluent cells were transfected by electroporation according to the protocol provided by BTX (San Diego, Calif). Briefly, cells were trypsinized, centrifuged, and washed twice with PBS; next, they were resuspended at a concentration of 2 ϫ 10 cells/mL in 1 mL of PBS containing 20 g of plasmid DNA (pSV and pLNCX-ribozyme). The cells and DNA mixture were loaded into a sterile 1.0-mL cuvette. A BTX manipulator 600 system was used to generate an exponential decay pulse with a set peak of 4.0 kV/cm and capacitance of 1100 F. After 24 hours, the mixture was placed in growth medium containing 500 g/mL geneticin (G418 sulfate, Life Technologies) for 24 weeks. G418-resistant colonies were picked up individually, grown, and screened for the expression of the K-ras ribozyme by RT-PCR assay. The colonies were again challenged with G418 for 8 weeks and tested for the presence of the neomycin gene. For the in vivo transfection assay, to determine the plasmid DNA delivery efficiency to the tumors, cationic liposome (Lipofectin, Life Technologies) was used as a control with the electroporation. Moreover, to send the electric current into the subcutaneous tumors of the mice, electrodes were attached to both sides of the tumor and direct current was applied using the BTX electroporation system. For luciferase assay, transfected cells were harvested after 48 hours, and light production by luciferase was assayed as a chemiluminescent with a luminescence analyzer (Berthold, Tokyo, Japan) according to Promega's Protocols and Application Guide. The optimal conditions were determined using a fixed amount of pGL3 plasmid DNA. The maximum level of luciferase activity was determined by cell lysates with pGL3 plasmid DNA as 1.
Animal studies
Five million tumor cells in a volume of 100 L of PBS were injected into male BALB/c nude mice at 5 weeks of age (Clea Japan, Tokyo, Japan). The mice were maintained under standard pathogen-free conditions and observed daily for evidence of tumor burden (i.e., weight loss, decreased activity, or impaired mobility). By electroporation using an electric needle, 10 g of plasmid DNA containing the ribozyme was transfected directly into tumors in each of the six groups for 4 days. The mice were then euthanized using CO 2 when they exhibited signs of distress or at 42 days. An MTT assay for drug sensitivity was performed on the separated cells obtained from tumors in each group.
RESULTS
Preliminary experiments showed that the ribozyme against activated K-ras oncogene (K-ras ribozyme) has the ability to cleave the targeted RNA in vitro (data not shown). Through the use of electroporation, the cultured SW620 cells were first transfected with pLNCX plasmid DNA containing K-ras ribozyme and subsequently treated with G418 for 3-6 weeks. Next, 12 G418-transfectant clones were selected based on the expression of K-ras ribozyme. RT-PCR analysis revealed the presence of the RNA transcripts of K-ras ribozyme in all of the G418-resistant colonies (Fig 2) . The expression of K-ras ribozyme was apparent in the cells for at least 6 weeks. Conversely, SW620 cells that were transfected with LNCX lacking the ribozyme sequences did not express the ribozyme. To determine whether the transfected ribozyme is able to act on the substrate RNA in the cells, we evaluated the mRNA levels of the target gene through Northern blot analysis (Fig 2) . The results revealed that K-ras ribozyme-positive clones (ribozymeC1, ribozymeC2, ribozymeC3, and ribozymeC4) had significantly decreased synthesis of K-ras mRNA compared with the synthesis in controls. However, there was no significant difference between K-ras ribozymepositive clones and controls in the expression of the H-ras gene. The levels of DNA synthesis determined by the [ 3 H]dThd incorporation assay were substantially lower in the KribozymeC1-4 clones ( Table 1 ). The plating efficiency in soft agar colony formation was also significantly lower in the KribozymeC clones compared with the control cells.
We compared the efficiency of transduction by electroporation and that by the Lipofectin method in a transient expression system using a reporter gene such as the luciferase gene (Fig 3) . The results showed marked differences of efficiency between the two methods; namely, the luciferase activity obtained from electroporation was significantly higher (more than four times) than that achieved using the Lipofectin method (Fig 3) . Light intensity indicating the presence of plasmid could not be detected in the cell lysates lacking the treatment with electroporation or cationic liposome or in those with the treatment but lacking the plasmid for the transfection. The nonspecific toxicity in the transfected cells was almost equal (Ͻ1% of total cells) between the transfected and mock-transfected cells (data not shown).
We confirmed the expression of ribozymes in the cells dispersed from tumors 4 weeks after the treatment with electroporation (Fig 4) . The expression of ribozymes lasted for at least 8 weeks in all of the mice with the ribozyme-inserted vector. DNA sequences in tumor samples were also revealed to include residual plasmid DNA when analyzed by PCR using control primers for plasmid (data not shown). The expression of K-ras mRNA in ribozyme-transfected tumors was low, but the expression of H-ras mRNA, irrelevant to K-ras mRNA, was not different between the ribozyme-transfected cells and the controls. The efficacy of the ribozyme was also tested for cell growth and for chemosensitivity in the in vitro system. The results revealed that both DNA synthesis and the plating efficiency in soft agar colony formation were significantly lower in KribozymeM1-4 tumors containing the K-ras ribozyme compared with parental cells and the vector only (Table 2) . Similar results were also obtained in the in vivo system; namely, the size of the tumors was smaller in athymic mice transfected with the K-ras ribozyme than in the controls when checked at 4 weeks posttransplantation.
We also evaluated the chemosensitivity of the cells to a variety of agents including 5-FU, ADR, VCR, CDDP, and VP16 (Table 3) . The original cells (SW620S) showed the native resistance to 5-FU at 12.41 nM/mL, to ADR at 2.36 nM/mL, to VCR at 4.57 nM/mL, to CDDP at 25.9 M/mL, and to VP16 at 16.4 nM/mL. In contrast, KribozymeM1-4 tumors transfected with K-ras ribozyme became more sensitive to each drug compared with the parental tumors. The sensitivity of KribozymeMI-4 tumors to the drugs was increased from 1.3-fold to 2.9-fold for 5-FU, from 6.3-fold to 21.4-fold for ADR, from 2.7-fold to 5.3-fold for VCR, from 2.4-fold to 4.7-fold for CDDP, and from 1.6-fold to 2.8-fold for VP16. However, the electric pulse-excited cells (SW620V) did not show increased sensitivity to the various agents.
DISCUSSION
An important factor in the strategy for cancer gene therapy is to select the genes for targeting. As has been reported previously, a mutation of the K-ras gene is common in pancreatic adenocarcinoma (ϳ90%), 9 lung adenocarcinoma (30%), 10 and adenocarcinoma of the colon (50%). 11 Recent data have also indicated that mutations of several oncogenes or suppressor genes such as p53, K-ras, and deleted in colorectal carcinoma(DCC) are required for carcinogenesis in human colon adenoma, 12 and that activation of the K-ras oncogene may play These experiments were performed with cells from tumors pulsed at the same time as in Table 1 . The expression of the ribozyme was assayed by RT-PCR. The [ 3 H]dThd uptake in SW620 cells was regarded as a control (100%) and was compared with the uptake in the other groups. SW620 cells (10 4 cells/35 mm 2 ) were grown in 0.3% soft agar with 20% fetal bovine serum. The numbers of colonies were counted 13 days later after Giemsa dye stain. an important role in tumorigenlicity. 13 This prompted us to target K-ras for antisense-mediated gene modulation in colon cancer, because colon cancer is one of the representative tumors that is relatively resistant to anticancer drug therapy, as also demonstrated in lung and pancreatic cancer.
14 -18 Therefore, as a therapeutic agent, we designed a hammerhead ribozyme that targets the activated codon 12 of K-ras but not antisense oligonucleotides, for the following reasons. First, ribozymes have the ability to specifically cleave the flanking site of mRNA, which potently blocks the transcription of the targeted mRNA. 7 Antisense oligonucleotides are able to selectively bind to the corresponding mRNA, but do not cleave it. 1 Further, ribozymes are inherently more resistant to ribonuclease and, therefore, more stable than antisense. In fact, preliminary experiments in an in vitro system confirmed that K-ras ribozyme was long-acting and more potent for the inhibition of mRNA expression.
An additional requirement for a successful strategy of gene targeting includes a delivery system to express the designed ribozyme in tumor cells. One is a virus-mediated system. However, this method has a risk that the infected virus might be cytotoxic and activate oncogenes in the targeted cells. 16 Therefore, we used necked DNA of plasmid because of they have fewer side effects for targeting organs. However, the question still remains of how to apply the delivery, because the viral transduction may be more effective than necked DNA of plasmid in gene delivery. Cationic liposome also has such drawbacks as nonspecific cytotoxicity in the cells. Therefore, we applied an electric pulse and long needles to effectively transfect the plasmid to cancer cells in vivo. 19, 20 The luciferase assay with a transient expression vector 21 revealed the efficiency of the plasmid DNA on tumors in mice as well as the continuous expression of the integrated ribozyme for Ͼ12 weeks, indicating the usefulness of electroporation as an effective system in vivo. Thus, our system brought about a successful reduction of tumor growth even in vivo. This also indicates that the K-ras ribozyme may act as a suppressor of the ras-activated cell growth of colon cancer both in vitro and in vivo.
Another important finding presented here is that treatment with the K-ras ribozyme caused enhanced sensitivity of the colon cancer to antitumoral agents in vivo as well as in vitro. Conversely, treatment with an electric pulse alone failed to induce enhanced sensitivity to drugs, indicating that the effect was attributable to the effect of the ribozyme, but not to the increased permeability at the cell membrane levels that may be induced by the electric pulse. It has been demonstrated that a variety of genes related to drug resistance, such as c-glycoprotein, are encoded by multidrug resistance genes. 22 This raises the possibility that manipulation of the expression of drug-resistant genes may contribute to increasing their sensitivity to anti-cancer agents, resulting in a reduction in tumor growth. Actually, cyclosporin and FK506 are known to inhibit c-glycoprotein. 23 We have also shown that the manipulation of c-fos expression may be effective for increasing the sensitivity to CDDP in ovarian or colon cancer cell lines. 8, 20 It was, however, still unclear which genes are responsible for the ineffectiveness to anti-cancer therapy in colon cancer, and there have been no reports indicating the expression of multidrug resistance, which enhances the excretion of anti-cancer agents from the cell membrane by enhancing its function as a pump. We have demonstrated the efficacy of anti-K-ras ribozyme with regard to increasing drug sensitivity. The data indicate that activated K-ras gene may be one of the unknown genes associated with drug resistance in colon cancers. The suppression of K-ras gene in colon cancer may have therapeutic potential in tumors. However, we do not yet have any data which contribute to an understanding of the mechanism of the increased drug sensitivity.
We have demonstrated the effectiveness of in vivo transfection of ribozyme for growth inhibition as well as for increasing the sensitivity to anti-cancer agents. Therefore, altered K-ras genes may be an important target for ribozyme strategies to enhance chemosensitivity in colon cancers. The cells from each group were obtained and exposed to drugs as described in Materials and Methods. SW620V was transfected with the vector not including the ribozyme and KRZM1-4 was transfected with the vector including the ribozyme. A total of 3000 cells in each group were incubated in a 35-mm 2 dish for 24 hours and subsequently treated with seven different concentrations of various drugs for 2 hours. After being washed with PBS twice, the cells were incubated for 5 days and measured for cytotoxicity to drugs by MTT assay. The results represent the mean Ϯ 2 SD of three separate experiments.
